Faculty of Dentistry, University of Indonesia
Jakarta Pusat, 10430, Indonesia
Location status: Recruiting
NCT Number: NCT07415733
The primary objective of this clinical study is to evaluate the impact on gingival health when participants switch to a fluoride toothpaste without gum-health actives for 4 weeks after using a proven gum-health toothpaste for 13 weeks.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Jakarta Pusat, 10430, Indonesia
Location status: Recruiting
This is a double-blind, randomized, controlled, parallel design study. A minimum of 150 participants (75 per group) will be enrolled according to the inclusion and exclusion criteria. The accepted participants will be randomly allocated to one of the two test products, which they will use at home twice daily for 13 weeks, followed by a switch to use a fluoride toothpaste without gum-health actives (the same formulation as the negative control) for an additional 4 weeks. Dental assessments of gingival condition, plaque levels and gingival bleeding will be performed at baseline, Weeks 4, 13 and 17. Gingival crevicular fluid (GCF) samples will be taken to detect biomarkers, and supragingival plaque samples will be collected to evaluate changes in microbial species relevant to gingival health. The Oral Health Impact Profile applied to Periodontal Disease (OHIP-14-PD) questionnaire will also be administered.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Toothpaste containing a gum-heath active and fluoride
Toothpaste containing fluoride
Time frame: Baseline, Week 17
The gingival condition will be assessed using gingival index (GI) [1]. The scoring criteria are: 0 = Absence of inflammation; 1 = Mild inflammation - slight change in colour and little change in texture; 2 = Moderate inflammation - moderate glazing, redness,oedema, and hypertrophy, bleeding on pressure; 3 = Severe inflammation - marked redness and hypertrophy, tendency to spontaneous bleeding, ulceration. Six sites on each tooth will be assessed, three on facial (buccal, mesial and distal) and three on palatal/lingual (palatal/lingual, mesial and distal) surfaces.
[1] LOE H, SILNESS J. Acta Odontol Scand. 1963;21:533-551.
Time frame: Baseline, Week 17
Plaque will be scored using a dichotomous index (presence or absence of plaque). The Full Mouth Plaque Score (FMPS, %) will be calculated as:
(Number of sites with plaque/Total number of sites assessed) × 100 [2]. Six sites per tooth will be assessed, three on facial (buccal, mesial and distal) and three on palatal/lingual (palatal/lingual, mesial and distal) surfaces.
[2] D'Elia G, Floris W, Marini L, et al. Dent J (Basel). 2023 Jul 17;11(7):172.
Time frame: Baseline, Week 17
Bleeding on Probing (BOP) is defined as the percentage of sites that bleed upon probing [3]. Six sites per tooth will be assessed: three on the facial surface (buccal, mesial, distal) and three on the palatal/lingual surface (palatal/lingual, mesial, distal).
[3] Joss A, Adler R, Lang NP. J Clin Periodontol. 1994;21(6):402-408.
Time frame: Baseline, Week 4, Week 13
The gingival condition will be assessed using gingival index (GI) [1]. The scoring criteria are: 0 = Absence of inflammation; 1 = Mild inflammation - slight change in colour and little change in texture; 2 = Moderate inflammation - moderate glazing, redness,oedema, and hypertrophy, bleeding on pressure; 3 = Severe inflammation - marked redness and hypertrophy, tendency to spontaneous bleeding, ulceration. Six sites per tooth will be assessed, three on facial (buccal, mesial and distal) and three on palatal/lingual (palatal/lingual, mesial and distal) surfaces.
[1] LOE H, SILNESS J. Acta Odontol Scand. 1963;21:533-551.
Time frame: Baseline, Week 4, Week 13
Plaque will be scored using a dichotomous index (presence or absence of plaque). The Full Mouth Plaque Score (FMPS, %) will be calculated as:
(Number of sites with plaque/Total number of sites assessed) × 100 [2]. Six sites per tooth will be assessed, three on facial (buccal, mesial and distal) and three on palatal/lingual (palatal/lingual, mesial and distal) surfaces.
[2] D'Elia G, Floris W, Marini L, et al. Dent J (Basel). 2023 Jul 17;11(7):172.
Time frame: Baseline, Week 4, Week 13
Bleeding on Probing (BOP) is defined as the percentage of sites that bleed upon probing [3]. Six sites per tooth will be assessed: three on the facial surface (buccal, mesial, distal) and three on the palatal/lingual surface (palatal/lingual, mesial, distal).
[3] Joss A, Adler R, Lang NP. J Clin Periodontol. 1994;21(6):402-408.
Time frame: Baseline, Week 4, Week 13 and Week 17
Gingival crevicular fluid (GCF) samples will be collected from a tooth site with gingival inflammation for each participant. Biomarkers will be analyzed from GCF samples using ELISA. Supragingival plaque will be collected from the same tooth site selected for GCF sampling. The microbiological status, based on the expression of bacteria will be analyzed from plaque sample through RT-PCR.
Time frame: Baseline, Week 4, Week 13 and Week 17
Quality of life will be evaluated using Oral Health Impact Profile Scale applied to Periodontal Disease (OHIP-14-PD) questionnaire [4]. The instrument consists of 14 questions covering seven dimensions: functional limitation, physical discomfort, psychological discomfort, physical disability, psychological disability, social disability and handicap.
[4] Rodríguez Franco NI, Moral de la Rubia J. The Open Dentistry Journal 2018, 12:1152-1161.
Contact information is provided by the study sponsor or research team.
Unilever R&D
Industry
A Randomized Clinical Study on the Effect of a Toothpaste Containing a Gum Health Active in Participants With Gingival Problem
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07364565
Dental Deposits, Dental Plaque
Irbid, Irbid Governorate, Jordan
View Trial DetailsNCT06752291
Dental Deposits, Dental Plaque
Kuala Lumpur, Malaysia
View Trial DetailsNCT03989427
Dental Deposits, Dental Plaque
Melaka Tengah, Melaka, Malaysia
View Trial DetailsNCT07100574
Atheroma Plaque, Dental Deposits
Istanbul, Turkey (Türkiye)
View Trial Details